Ipamorelin Reconstitution Calculator

No. Ipamorelin is not FDA-approved for any indication and remains an investigational growth hormone secretagogue (ghrelin receptor agonist). Human clinical study exists, including a randomized proof-of-concept trial in postoperative ileus, but that does not equal regulatory approval.

Ipamorelin stimulates growth hormone (GH) release through the ghrelin receptor (GHS-R1a) and is distinguished by relatively high selectivity for GH release with minimal ACTH, cortisol, and prolactin stimulation compared with older GHRPs (human pharmacology/preclinical). In practical terms, it is used to raise pulsatile GH output and secondarily IGF-1, usually for body-composition, recovery, or “GH support” goals, but robust human efficacy data for muscle gain or fat loss are limited.

Published human studies establish pharmacologic activity, but routine outpatient dosing for body-composition goals is mostly extrapolated from research and practitioner use rather than formal approval trials (human PK/PD + community protocol). Common practice is 100–300 mcg subcutaneously 1–3 times daily, often 200 mcg once nightly or 200 mcg 2×/day; body-weight adjustment is usually unnecessary because users titrate to IGF-1 response and tolerability rather than mg/kg (community protocol). Some fertility-case-report use employed 200 mcg SC daily [case report in corpus, not strong efficacy evidence].

Subcutaneous is the standard route for reliable effect (human PK/PD). Intranasal absorption has been studied, but peptide bioavailability by non-injectable routes is generally lower and less predictable than injection, so SC is preferred when the goal is consistent GH stimulation.

For GH-axis use, most people dose before bed and/or fasted between meals to better preserve physiologic GH pulsatility and avoid blunting from feeding-related insulin and glucose signals (mechanistic/practitioner consensus). Common timing is 30–60 minutes before sleep, or morning fasted plus bedtime if using twice daily (community protocol).

There is no well-defined long-term evidence-based duration for non-approved wellness or physique use (human data limited). Community cycles are commonly 8–12 weeks, sometimes 12–16 weeks, followed by reassessment of IGF-1, fasting glucose, edema, appetite changes, and subjective benefit (community protocol). Longer continuous use is possible in practice, but the main limitation is absence of long-term safety data rather than a clearly proven tachyphylaxis threshold.

Compared with GHRP-2 and GHRP-6, ipamorelin is notably more selective and was described as the first GHRP without significant cortisol stimulation at studied doses (human pharmacology). Appetite increase can still occur because it acts at the ghrelin receptor, but it is generally considered less orexigenic than some earlier secretagogues (mechanistic/review).

Ipamorelin is a short-acting ghrelin-receptor agonist that produces acute GH pulses; CJC-1295 is a GHRH analog that amplifies pituitary GH signaling through a different receptor, and the combination is used to target both pathways (mechanistic/review). MK-677 is oral and longer-acting, producing more sustained GH/IGF-1 elevation over ~24 hours, but it is more often associated with appetite increase and insulin-resistance concerns than short-acting peptide secretagogues (review). For users prioritizing tighter dosing control and less persistent hunger, ipamorelin is often favored; for convenience, MK-677 is favored (practitioner consensus).

Human and review data suggest the main expected issues are transient flushing, headache, lightheadedness, increased appetite, mild water retention, and injection-site irritation; endocrine overstimulation is less prominent than with less selective GHRPs (human/review). Because the GH/IGF-1 axis is being stimulated, prudent monitoring includes fasting glucose, HbA1c if prolonged use, IGF-1, edema, numbness/tingling, and blood pressure trends (practitioner consensus).

Possible, but expectations should be modest (review/human-limited). GH secretagogues can raise IGF-1 and may modestly improve lean mass or recovery, but clear, high-quality human evidence for large standalone physique effects is lacking; diet, training, sleep, and energy balance remain the main drivers.

Avoid routine use in pregnancy and breastfeeding because adequate maternal-fetal safety data do not exist (human data lacking). A small fertility case series reported 200 mcg/day in women with ovarian insufficiency within a broader multimodal protocol, but this is uncontrolled, confounded, and not sufficient to establish safety or efficacy for reproductive use (case series). If conception is attempted or possible, discontinuation is the conservative approach (practitioner consensus).

Yes. Growth hormone secretagogues, including ipamorelin, are prohibited in sport and are actively targeted in anti-doping testing (antidoping/review). Urine and dried-blood-spot analytical methods have identified parent compound and metabolites, so detection risk is real rather than theoretical.